Anesthetic concerns for patients with coagulopathy

Current Opinion in Anaesthesiology

Volumn 23, Issue 3, 2010, Pages 400-405

  Levy, Jerrold H ^a   Azran, Marc ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Bleeding; Surgery; Thrombin inhibitors; Xa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; DANAPAROID; DESMOPRESSIN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; FRESH FROZEN PLASMA; GELATIN SPONGE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RIVAROXABAN; THROMBIN; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

BLEEDING; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY STENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; HEART ATRIUM FIBRILLATION; HEMOPHILIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM PLASMA CONCENTRATION; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; SURGICAL PATIENT; VENOUS THROMBOEMBOLISM;

ANESTHESIA; FIBRINOGEN; HEMATOLOGIC AGENTS; HEMOSTATIC DISORDERS; HUMANS;

EID: 77952005024     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328339480a     Document Type: Review

References (72)

1. Levy JH, Dutton RP, Hemphill JC 3rd, et al. Multidisciplinary approach to the •• challenge of hemostasis. Anesth Analg 2009. Recent review about issues relevant to this chapter.
2. Adams GL, Manson RJ, Turner I, et al. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am 2007; 21: 13-24.
3. Steinhubl SR, Schneider DJ, Berger PB, Becker RC. Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. J Thromb Thrombolysis 2007.
4. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American •• College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 234S-256S. Recent guidelines on the management, and an important review. (Pubitemid 351892968)
5. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311.
6. Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol 2004; 41: 55-64.
7. Achneck HE, Sileshi B, Lawson JH. Review of the biology of bleeding and • clotting in the surgical patient. Vascular 2008; 16 Suppl: S6-S13. Recent review on surgical hemostasis.
8. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res 2007; 100: 174-190.
9. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100: 158-173.
10. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin •• regulation. Anesth Analg 2009; 108: 1433-1446. Definitive review of hemostasis.
11. Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemo-• stasis. J Thromb Haemost 2009; 7: 1759-1766. Definitive review of hemostasis.
12. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007; 21: 1-11.
13. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth • Analg 2009; 108: 1447-1452. Definitive review of hemostasis.
14. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 5: 1097-1105.
15. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86: 139-146.
16. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
17. Levy JH. Novel intravenous antithrombins. Am Heart J 1043; 141: 7.
18. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004; 100: 722-730.
19. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
20. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 1999; 91: 1122-1151.
21. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
22. Eikelboom JW, Weitz JI. A replacement for warfarin: the search continues. Circulation 2007; 116: 131-133.
23. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the •• vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S. Recent guidelines from ACCP. (Pubitemid 351892967)
24. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000; 60: 347-377.
25. Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res 2007; 121: 413-418.
26. Tanaka KA, Szlam F, Kelly AB, et al. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets 2004; 15: 325-332.
27. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
28. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and noncardiac surgery: a prospective outcome study. Br J Anaesth 2006; 96: 686-693.
29. Serebruany V, Shalito I, Kopyleva O. Prasugrel development: claims and achievements. Thromb Haemost 2009; 101: 14-22.
30. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
31. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002; 76 (Suppl 2) : 139-144.
32. Levy JH. Pharmacologic methods to reduce perioperative bleeding. Transfusion 2008; 48: 31S-38S.
33. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 2008; 106: 392-403.
34. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-694.
35. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-253.
36. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521.
37. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991; 74: 988-996.
38. Rocha E, Llorens R, Paramo JA, et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988; 77: 1319-1323.
39. Salzman EW, Weinstein MJ, Reilly D, Ware JA. Adventures in hemostasis. Desmopressin in cardiac surgery. Arch Surg 1993; 128: 212-217.
40. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986; 314: 1402-1406.
41. Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988; 71: 1648-1655.
42. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery: a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995; 74: 1064-1070.
43. Levy JH. Hemostatic agents. Transfusion 2004; 44: 58S-62S.
44. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001; 72: S1814-S1820.
45. Steiner ME, Key NS, Levy JH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol 2005; 18: 89-92.
46. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
47. Camerer E, Huang W, Coughlin SR. Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-5260.
48. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant • activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120: 21-27. A randomized study of VIIa in cardiac surgery.
49. Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006; 46: 919-933.
50. Levi M, Bijsterveld NR, Keller TT. Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004; 41: 65-69.
51. Pruthi RK, Mathew P, Valentino LA, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-732.
52. Duchesne JC, Mathew KA, Marr AB, et al. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg 2008; 74: 1159-1165.
53. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44: 1325-1331.
54. Despotis G, Avidan M, Lublin DM. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Ann Thorac Surg 2005; 80: 3-5.
55. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44: 1143-1148.
56. Furnary AP, Wu Y, Hiratzka LF, et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116: I127-I133.
57. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications • after cardiac surgery. N Engl J Med 2008; 358: 1229-1239. An important analysis of the role of transfusion in adverse outcomes.
58. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of •• patients treated with vitamin K antagonists. Anesthesiology 2008; 109: 918-926. Recent review of the management.
59. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 82: 1091-1094.
60. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006; 26: 1091-1098.
61. Lankiewicz MW, Hays J, Friedman KD, et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
62. Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost 2006; 4: 963-966.
63. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119: 643-651.
64. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101-1107.
65. Nielsen VG, Levy JH. Fibrinogen and bleeding: old molecule-new ideas. Anesth Analg 2007; 105: 902-903.
66. Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006; 43: S59-63.
67. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5: 266-273.
68. Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal concentration range • for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009 Data supporting fibrinogen's role in treating bleeding.
69. Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23: 177-188.
70. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 2006; 32 (Suppl 1) : 98-110.
71. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005; 79: 1037-1038.
72. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.